***See editorial vol. 27: 6--7***

Introduction
============

Although the prognosis after suffering from atherosclerotic cardiovascular disease (ASCVD) has been improved with the introduction of primary coronary angioplasty as well as medical treatment such as LDL-lowering therapies and anti-platelet therapies^[@bib1]--[@bib3])^, secondary prevention of these patients is still one of the major challenges for cardiologists. Identifying individuals at the higher risk for recurrent cardiovascular events and, then, aggressively addressing modifiable risk factors in these individuals may be beneficial regarding health outcomes and cost.

Carotid intima--media thickness (cIMT) determined by less-invasive ultrasonography has been shown to be a surrogate marker for coronary atherosclerosis^[@bib4])^, and increased cIMT has been shown to be associated with future cardiovascular events^[@bib5]--[@bib7])^. On the other hand, carotid plaque score (cPS) reflecting throughout the carotid artery plaque burden may be better marker. Our previous study has shown that the carotid plaque score (cPS), reflecting the cumulative atherosclerotic burden of the carotid artery, is a more useful parameter to predict the atherosclerotic severity of the coronary artery than cIMT in patients with familial hypercholesterolemia (FH)^[@bib8])^. Some previous studies have shown that cPS or carotid plaque burden was better marker for severity of coronary artery disease or the first cardiovascular events among primary prevention group^[@bib9],\ [@bib10])^. However, few data exist regarding the clinical impact of cPS on the recurrence of ASCVD, comparing that of cIMT in a setting of secondary prevention. Accordingly, we aimed to compare the prognostic utility of these measurements among patients with ASCVD. Moreover, such modality could help us to estimate when and how rapidly coronary atherosclerosis in patients with ASCVD develop^[@bib8],\ [@bib11])^. Accordingly, we aimed (1) to compare the prognostic utility of these measurements and (2) to estimate the onset and progression of carotid atherosclerosis in patients of a secondary prevention setting.

Materials and Methods
=====================

Study Subjects
--------------

In total, 2,132 consecutive patients who had any histories of ASCVD events and underwent carotid ultrasonography between January 2006 and December 2015 were retrospectively analyzed. Among the 2,132 patients, 97 patients lacking data (5 %) were excluded (**[Supplemental Fig. 1](#F5){ref-type="fig"}**). Thus, 2,035 patients with ASCVD whose ages ranged from 14 to 95 years were included in the analysis (male = 1,253, mean age = 65 ± 12 years, mean LDL cholesterol = 115 ± 36 mg/dL).

![Flow chart of this study\
In total, 2,132 consecutive patients who had any histories of ASCVD events and underwent carotid ultrasonography between January 2006 and December 2015 were retrospectively analyzed. Ninety seven patients lacking data (5%) were excluded.](jat-27-38-g005){#F5}

Clinical Evaluations
--------------------

Blood samples were drawn for assays after overnight fasting. Serum levels of total and HDL cholesterol and triglycerides were enzymatically determined (Qualigent, Sekisui Medical, Tokyo, Japan) using automated instrumentation based on previously described assays^[@bib12])^. Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg or treatment with antihypertensive medications. The presence of diabetes was defined as described previously by the Japan Diabetes Society^[@bib13])^. Smoking status was defined as current smoking habits. Left ventricular ejection fraction (LVEF) was calculated either by modified Simpson\'s method or by Teichholz method. We defined major adverse cardiac events (MACE) as either all-cause death, including cardiac death, ST elevated myocardial infarction (STEMI), non-ST elevated myocardial infarction (NSTEMI), unstable angina pectoris (UAP), staged percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), ischemic as well as hemorrhagic stroke, heart failure requiring hospital admission.

Carotid Ultrasonography
-----------------------

The parameters for carotid ultrasonography were measured using the Aplio carotid ultrasonography machine (Toshiba Medical Systems, Tokyo, Japan) with a 7.5-MHz transducer by trained sonographers who were blinded to the clinical data. cIMT was recorded during ultrasonography as described previously^[@bib14])^. In brief, cIMT from the right and left sides was measured from the far wall, the location of which was identified as the vertical distance from the leading edge of the first to the second echogenic line. Three cIMT determinations were measured in the walls at the site of the greatest thickness for each common carotid artery, and these measurements of both the arteries were averaged and expressed as the mean cIMT. In addition, cPS was computed by summing the maximal thickness of plaques, that were defined as focal intima--media thickening ≥ 1.1 mm, in each segment on both sides (a+b+c+thickness of the contralateral plaques in each segment on both sides) as described previously^[@bib8],\ [@bib15])^.

Ethical Consideration
---------------------

The Ethics Committee of Kanazawa University approved this study. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, revised in 2008. Informed consent was obtained from all the subjects for inclusion in the study.

Statistical Analysis
--------------------

Continuous variables are presented as mean ± standard deviation, and categorical variables are expressed as counts and percentages. For values lacking a normal distribution, the median and interquartile range are reported. Mean values of continuous variables were compared using Student\'s *t*-test for independent data, and median values were compared using the nonparametric Mann Whitney *U*-test/Wilcoxon rank-sum test. Categorical variables were compared using the chi-square test. Hazard ratios were determined adjusted for age, sex, hypertension, current smoking, triglyceride, LDL cholesterol, HDL cholesterol, anti-platelet therapy, and lipid-lowering therapy. Hazard ratios for occurrence of endpoint events were determined for each quintile of cPS, with quintile 1 serving as the referent group. The cumulative fraction of events was estimated as 1 minus the Kaplan-Meier estimate of survival free of event. The differences of the cumulative fraction of events between subgroups were assessed by the log-rank test. Receiver-operating characteristic analysis was performed and C-statistic was calculated to estimate the predictive performance of the evaluated parameters. C-statistic estimates were compared using the method of DeLong *et al.* Intraobserver/interobserver variability between sonographers was assessed using the Bland-Altmann method, and coefficient of variation (CV) with 40 randomly selected subjects. A *p* value of \< 0.05 was considered statistically significant. Statistical analysis was performed using R version 3.3.2.

Results
=======

Reproducibility of Measurements
-------------------------------

**[Supplemental Fig. 2](#F6){ref-type="fig"}** and **[Supplemental Fig. 3](#F7){ref-type="fig"}** show intra- and interobserver reproducibility for measurements of cIMT and cPS. Bland-Altman analysis demonstrated good agreements between both within intraobserver with a CV of 9.1%, 10,4% and within interobserver with a CV of 9.9%, 11.1% for measurements cIMT, and cPS, respectively.

![Bland-Altmann plot of cIMT\
X-axis represents mean of the difference. Y-axis represents difference. (A) Intraobserver. (B) Interobserver.](jat-27-38-g006){#F6}

![Bland-Altmann plot of cPS\
X-axis represents mean of the difference. Y-axis represents difference. (A) Intraobserver. (B) Interobserver.](jat-27-38-g007){#F7}

Baseline Characteristics
------------------------

**[Table 1](#T1){ref-type="table"}** illustrates the baseline characteristics of the study population. We observed 243 MACE events during the median 4 years of follow-up period. **[Table 2](#T2){ref-type="table"}** illustrates details of MACE. As expected, the patients with MACE were significantly older than those without ASCVD. Frequencies of other traditional risk factors such as male gender, hypertension, diabetes, and smoking habits were significantly higher and that of HDL cholesterol was significantly lower in patients with MACE than in those without. Under these conditions, cIMT and cPS were significantly higher in patients with MACE than in those without. **[Fig. 1](#F1){ref-type="fig"}** illustrates distribution of cIMT as well as cPS.

###### Baseline characteristics

  ----------------------------------------------------------------------------------------------------------------------
  Variable                                       All\                MACE                 *p* value           
                                                 (*n* = 2,035)                                                
  ---------------------------------------------- ------------------- -------------------- ------------------- ----------
  Age (years)                                    65 ± 12             69 ± 9               65 ± 13             \< 0.001

  Men                                            1,253 (62 %)        187 (77 %)           1,066 (59 %)        \< 0.001

  Hypertension                                   1,459 (72 %)        220 (91 %)           1,239 (69 %)        \< 0.001

  Diabetes                                       841 (41 %)          138 (57 %)           703 (39 %)          \< 0.001

  Smoking                                        1,122 (55 %)        196 (81 %)           926 (52 %)          \< 0.001

  Total cholesterol (mg/dL)                      192 ± 42            180 ± 40             194 ± 42            \< 0.001

  Low-density lipoprotein cholesterol (mg/dL)    115 ± 36            108 ± 34             116 ± 37            0.004

  High-density lipoprotein cholesterol (mg/dL)   52 ± 16             46 ± 13              53 ± 16             \< 0.001

  Triglyceride (mg/dL)                           106 \[75--154\]     108 \[75.156\]       106 \[73--154\]     0.79

  Anti-platelet therapy                          1,983 (97 %)        241 (99 %)           1,742 (97 %)        0.142

  Lipid-lowering therapy                         1,846 (91 %)        236 (97 %)           1,610 (90 %)        \< 0.001

  Carotid IMT (mm)                               0.8 \[0.7--1.0\]    1.0 \[0.8--1.1\]     0.8 \[0.7--1.0\]    \< 0.001

  Carotid plaque score                           7.4 \[3.4--12.3\]   12.2 \[8.0--16.5\]   6.8 \[3.1--11.4\]   \< 0.001
  ----------------------------------------------------------------------------------------------------------------------

MACE: major adverse cardiac events, IMT: intima-media thickness

###### Type of MACE

  Type of MACE                          Number (%)
  ------------------------------------- ------------
  All-cause death                       89 (36%)
      death associated with ASCVD       53 (22%)
      death not-associated with ASCVD   36 (15%)
  Cardiovascular disease                89 (37%)
      STEMI                             7 (3%)
      NSTEMI                            17 (7%)
      UAP                               18 (7%)
      staged PCI/CABG                   47 (19%)
  Stroke                                19 (8%)
      ischemic stroke                   14 (6%)
      hemorrhagic stroke                5 (2%)
  Heart failure                         46 (19%)

MACE: major adverse cardiac events, ASCVD: atherosclerotic cardiovascular disease, STEMI: ST-elevated myocardial infarction, NSTEMI: non ST-elevated myocardial infarction, UAP: unstable angina pectoris, PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft

![Distribution of carotid IMT and carotid plaque score\
(A) X-axis represents carotid IMT (cm). Y-axis represents frequency.\
(B) X-axis represents carotid plaque score (cm). Y-axis represents frequency.](jat-27-38-g001){#F1}

Factors Associated with MACE
----------------------------

Next, we investigated the factors associated with MACE, including carotid ultrasonographic parameters (**[Table 3](#T3){ref-type="table"}**). cPS was significantly associated with MACE (HR = 1.08, 95%CI, 1.04--1.12, *p* \< 0.001) after adjustment for established risk factors including age, gender, hypertension, diabetes, smoking, triglyceride, LDL cholesterol, HDL cholesterol, and LVEF, while cIMT was not associated with MACE (HR = 0.89, 95%CI, 0.52--1.49, *p* = 0.61).

###### Factors associated with MACE

  Variables                HR (95%CI)             *p*-value
  ------------------------ ---------------------- -----------
  Age                      1.017 (1.00 -- 1.03)   0.02
  Gender                   1.41 (1.04 -- 1.85)    0.007
  Hypertension             1.49 (1.09 -- 2.16)    0.004
  Diabetes                 1.20 (0.90 -- 1.74)    0.18
  Smoking                  1.85 (1.25 -- 2.70)    0.002
  Triglyceride             0.99 (0.99 -- 1.00)    0.027
  LDL cholesterol          0.996 (0.99 -- 1.00)   0.09
  HDL cholesterol          0.95 (0.90 -- 1.00)    0.002
  Anti-platelet therapy    1.28 (0.91 -- 1.80)    0.21
  Lipid-lowering therapy   0.91 (0.63 -- 1.28)    0.55
  LVEF                     1.03 (1.01 -- 1.05)    0.021
  Carotid IMT              0.89 (0.52 -- 1.40)    0.61
  Carotid plaque score     1.08 (1.04 -- 1.12)    \< 0.001

MACE: major adverse cardiac events, LVEF: left ventricular ejection fraction, IMT: intima-media thickness

The Power of cPS for Predicting MACE
------------------------------------

When the patients were divided into 5 groups based on cPS quintiles, those with the highest cPS had 3.38 fold greater risk of MACE than those with lowest quintile (95%CI 1.82--6.27, *p* \< 0.001 vs. lowest cPS, **[Table 4](#T4){ref-type="table"}**). Moreover, cumulative MACE rate increased according to quintile of the cPS (Log-rank trend, *p* \< 0.001, **[Fig. 2](#F2){ref-type="fig"}**).

###### Impact of carotid plaque score on MACE

                       Carotid plaque score Quintile   *P*~trend~                                                                              
  -------------------- ------------------------------- --------------------- --------------------- --------------------- --------------------- ----------
  MACE                                                                                                                                         
  Number (Events)      421 (20)                        408 (21)              402 (38)              407 (57)              407 (107)             
  HR (95%CI)           Reference                       0.80 (0.41 -- 1.57)   1.47 (0.81 -- 2.67)   1.84 (1.01 -- 3.36)   3.38 (1.82 -- 6.27)   \< 0.001
  *P* value (vs. Q1)                                   0.52                  0.2                   0.047                 \< 0.001              

cPS: carotid plaque score, MACE: major adverse cardiac events, HR: Hazard ratio, Q: quintile

![Cumulative event rate divided by carotid plaque score quintile\
X-axis represents follow-up period (year). Y-axis represents event rate.\
Red dotted line indicates quintile 5. Green dotted line indicates quintile 4. Black dotted line indicates quintile 3. Blue dotted line indicates quintile 2. Light blue solid line indicates quintile 1.](jat-27-38-g002){#F2}

Risk Discrimination by cPS
--------------------------

We investigated whether the discrimination of a model based on the established traditional risk factors, including age, gender, hypertension, diabetes, smoking, triglyceride, LDL cholesterol, and HDL cholesterol differed from that of a model that also included cPS. The C-statistic for the traditional risk factors model was 0.726, which increased to 0.746 (**[Fig. 3](#F3){ref-type="fig"}**, *p* = 0.01748) after the addition of cPS information to the model. To assess the discriminatory potential of these parameters, we also assessed the continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI). We found that the addition of cIMT or cPS to the traditional risk factor model improved reclassification (continuous NRI = 0.227, 95% CI = 0.106--0.358, *p* \< 0.001; IDI = 0.0103, 95% CI = 0.0021--0.0365, *p* = 0.048; continuous NRI = 0.481, 95% CI = 0.234--0.733, *p* \< 0.001; IDI = 0.021, 95% CI = 0.0051--0.102, *p* \< 0.001, **[Table 5](#T5){ref-type="table"}**).

![Receiver-operating characteristic curve\
The black line (model 1) indicates the receiver-operating characteristic curve using traditional risk factors, including age, gender, hypertension, diabetes, smoking, triglyceride, LDL cholesterol, HDL cholesterol. The red line (model 2) indicates the receiver-operating characteristic curve using traditional risk factors and carotid plaque score.](jat-27-38-g003){#F3}

###### Risk discrimination by carotid intima--media thickness or carotid plaque score beyond traditional risk factors

               NRI (95% CI)           *p* value   IDI (95% CI)              *p* value
  ------------ ---------------------- ----------- ------------------------- -----------
  TRF          Reference              Reference                             
                                                                            
  TRF + cIMT   0.227 (0.106--0.358)   \< 0.001    0.0103 (0.0021--0.0365)   0.048
                                                                            
  TRF + cPS    0.481 (0.234--0.733)   \< 0.001    0.021 (0.0051--0.102)     \< 0.001

CI, confidence interval; HR, hazard ratio; NRI, net reclassification improvement; IDI, integrated discrimination improvement; TRF, traditional risk factors (age, gender, hypertension, diabetes, smoking, triglyceride, LDL cholesterol, and HDL cholesterol)

Development of Carotid Plaque
-----------------------------

Finally, we evaluated the correlation coefficient between age and cPS in each gender (**[Fig. 4](#F4){ref-type="fig"}**). The regression equations were Y = 0.245X−6.63 (*r* = 0.50, *p* \< 0.001) in male and Y = 0.189X−6.09 (*r* = 0.469, *p* \< 0.001) in female. These results suggest that carotid atherosclerosis had already started to develop, on average, at 27 and 32 years of age in male and female patients with ASCVD, respectively.

![Plots of correlation between age (X) and carotid plaque score (Y) in male (A) and female (B) patients with ASCVD\
The regression equations were Y = 0.245X−6.63 (*r* = 0.50, *p* \< 0.001) in male and Y = 0.189X−6.09 (*r* = 0.469, *p* \< 0.001) in female.](jat-27-38-g004){#F4}

Discussion
==========

The present study compared the clinical utility of 2 different measurements obtained from carotid ultrasonography in patients with ASCVD. This study provides the following important evidence: (1) cPS, rather than cIMT is an independent predictor of MACE (2) cPS is an useful clinical tool for risk stratification (3) On average, carotid atherosclerosis may start to develop at 27 and 32 years of age in male and female patients in a secondary prevention setting, respectively.

Despite the significantly elevated cardiovascular disease risk in patients of a secondary prevention setting, their individual risk is heterogeneous^[@bib16]--[@bib19])^. Further risk stratification strategies would be needed to pin-point extreme high-risk individuals. We have shown previously that plaque burden in coronary arteries assessed by coronary computed tomography angiography was associated with future ASCVD events in patients with FH^[@bib11])^. In this study, cPS which could be assessed non-invasively, compared with coronary computed tomography angiography, was independently associated with recurrent ASCVD events, while cIMT was not. Although several investigators have examined the predictive value of cIMT and other metrics obtained from carotid ultrasonography, few studies have specifically compared the prognostic value of cIMT and cPS. In the present study, we demonstrated that compared with cIMT, cPS may provide superior risk stratification in patients of a secondary prevention setting. It is not surprising that the calculation of cPS, which is a reflection of the cumulative atherosclerotic burden in the carotid artery, is superior in predicting future cardiovascular events compared with the calculation of IMT in the common carotid artery. Additionally, cIMT shows normal distribution, and even extremely low-risk individuals do not exhibit score of "zero". Moreover, the absolute difference between high-risk and low-risk individuals is small. On the other hand, cPS reflects the sum of the "plaque" whose intima--media thickening ≥ 1.1 mm, leading to reflect higher risk situation compared to cIMT. This factor could contribute to enhance the power of cPS especially among the patients with secondary prevention setting. Additionally, cPS could also reflect lower risk situation because of the powerful negative predictive value^[@bib9])^. Those factors appear to collectively contribute to better risk discriminatory power of cPS, compared with cIMT. Moreover, cPS has been shown as an useful marker for good predictor of cardiovascular mortality even in the very old population^[@bib20])^. Accordingly, we suggest to assess cPS, rather than cIMT for the risk stratification and as a surrogate marker for the progression of atherosclerosis in patients of a secondary prevention settings, as suggested in the patients with FH.

Based on regression lines from age and cPS among FH patients, we previously reported that carotid atherosclerosis may start to develop at 17 and 26 years of age in male and female FH patients, respectively^[@bib8])^. In this study, we performed the same analyses, and found that carotid atherosclerosis starts to develop at 27 and 32 years of age in male and female patients of a secondary prevention settings, respectively. These results suggest that carotid atherosclerosis might have already started to develop, at those early ages in particular high-risk population. Therefore, initiating lipid-lowering therapy should be considered before such ages in this high-risk population.

The present study had several limitations. First, this was a retrospective study with a small sample size. In addition, we could not include all patients who underwent carotid ultrasonography in the study due to the lack of data. Second, we did not account for medication information, which could affect cIMT and cPS. Third, our assumption of the development of carotid atherosclerosis in such patients is based on a linear model, which may not be applicable to those individuals. Further prospective studies accounting for those limitations are needed to validate our results.

We express special thanks to Ms. Kazuko Honda, Ms. Takako Terakami, Mr. Yoshiyasu Miyajima, and Mr. Sachio Yamamoto (staff of Kanazawa University) for their technical assistance in this study.

Conflicts of Interest
=====================

None.
